RxDoctor Payments Data

Monica Ahluwalia, MD

Advanced Heart Failure and Transplant Cardiology · Boston, MANPI 1942645775

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $34,890 of the $39,447 with a category attached, or 88.4%. E.r. Squibb & Sons, L.L.C. accounts for 93.5% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $16,197, more than ten times the $177 reported in 2019.

$39,447in general payments, 2019–2025

Across 36 payments — averaging $1095.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$37K
  • Alnylam Pharmaceuticals Inc.$2K
  • Abbott$134
  • Novartis$23
$412,559in research payments, 2019–2025

Across 5 payments — averaging $82,512 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$413K

What the payments were for

  • Consulting fees$34,89088%
  • Travel & lodging$3,3569%
  • Food & beverage$1,2013%

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,447 in reported general payments places this provider in the 80th percentile of 35 advanced heart failure and transplant cardiology providers in Massachusetts.

See all advanced heart failure and transplant cardiology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$40,888
Medicare patients
176
Services billed
426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CamzyosMavacamten53$438,042
JardianceEmpagliflozin29$15,910
EntrestoSacubitril/Valsartan20$13,506
Metoprolol Succinate50$1,285
Nifedipine ErNifedipine11$167
Spironolactone22$118
Losartan Potassium16$96
Furosemide14$35

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$36,889$438,04253 claims
NovartisEntresto$23$13,50620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 35 advanced heart failure and transplant cardiology providers in Massachusetts.

Other advanced heart failure and transplant cardiology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →